Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 4, 2007, Pages 831-836

  Seminari, Elena ^a   De bona, Anna ^a   Gentilini, Gianluca ^a   Galli, Laura ^a   Schira, Giulia ^a   Gianotti, Nicola ^a   Uberti foppa, Caterina ^a   Soldarini, Armando ^a   Dorigatti, Fernanda ^a   Lazzarin, Adriano ^a   Castagna, Antonella ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Cirrhosis; HBV; HCV; Pharmacokinetics

Indexed keywords

AMPRENAVIR PHOSPHATE; AMPRENAVIR PHOSPHATE PLUS RITONAVIR; BILIRUBIN; PROTEINASE INHIBITOR; RITONAVIR; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MONITORING; DRUG SAFETY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; LIVER FUNCTION; MALE; STEADY STATE;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; ATTENTION; BILIRUBIN; CARBAMATES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HIV INFECTIONS; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; PHOSPHORIC ACID ESTERS; PLASMA; RITONAVIR; SULFONAMIDES; TIME FACTORS;

EID: 34548706470     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm282     Document Type: Article

References (18)

1. Veronese L, Rautaureau J, Sadler BM et al. Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function. Antimicrob Agents Chemother 2000; 44: 821-6.
2. Tachikawa N, Yoshizawa S, Kikuchi Y et al. Saquinavir therapy in patients with advanced HIV infection and liver cirrhosis. Jpn J Infect Dis 1999; 52: 177-8.
3. Regazzi M, Maserati R, Villani P et al. Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects. Antimicrob Agents Chemother 2005; 49: 643-9.
4. Mallolas J, Perez-Elias MJ, Ortega E et al. Fosamprenavir(FPV)/ ritonavir(rtv) dose adjustment for patients with mild and moderate hepatic impairment (HI) (APV10017). In: Abstracts of the Eighth International Workshop on Clinical Pharmacology of HIV Therapy, Budaest, Hungary, 2007. Abstract 1.
5. Sulkowski MS, Thomas DL, Chaisson RE et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 74-80.
6. Hugen PW, Verweij-van Wissen CP, Burger DM et al. Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1999; 727: 139-49.
7. Shah VP, Midha KK, Findlay JWA et al. Bioanalylicall method validation - a revisit with a decade of progress. Pharm Res 2000; 17: 1551-7.
8. Wood R, Arasteh K, Stellbrink HJ et al. Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 2004; 48: 116-23.
9. 1-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother 2001; 45 852-6.
10. Norvir (ritonavir). Prescribing information (USA). North Chicago, IL: Abbott Laboratories.
11. Shelton MJ, Wire MB, Lou Y et al. Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir. Antimicrob Agents Chem 2006; 50: 928-34.
12. Cameron DW, Valdes J, Garber G et al. Ritonavir pharmacokinetics in HIV-infected patients with underlying hepatic disease. In: Abstracts of the Fifth Conference on Retrovirus and Opportunistic Infections, Chicago, IL, 1998 Abstract 359. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
13. Peng J, Bertz R, Hsu A et al. Evaluation of single and multiple dose pharmacokinetics of ritonavir in subjects with mild or moderate hepatic insufficiency. In: Abstracts of the Fourth International Workshop on Clinical Pharmacology of HIV Therapy, Cannes, France, 2003 Abstract 16, p.3.7.
14. Becquerhont L, Chazouilleres O, Serfaty L et al. Effect of interferon α-ribavirin biotherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransterase-2 activities in patients with chronic active hepatitis C. Clin Pharm Ther 2002; 71: 488-95.
15. Peng JZ, Pulido F, Causemaker SJ et al. Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment. J Clin Pharmacol 2006; 46: 265-74.
16. Sulkowski MS, Mehta SH, Chaisson RE et al. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 2004; 18: 2277-84.
17. Mocroft A, Soriano V, Rockstroh J et al. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS 2005; 19: 2117-25.
18. Canta F, Marrone R, Bonora et al. Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients. J Antimicrob Chemother 2005; 55: 280-1.